TY - JOUR T1 - Association of plasma level of Mixed lineage kinase domain-like protein with severity and outcome of sepsis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3764 VL - 58 IS - suppl 65 SP - PA3764 AU - Hongseok Yoo AU - Jin Young Lee AU - Junseon Park AU - Kyeongman Jeon Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3764.abstract N2 - Background: Previous studies have suggested that necroptosis, a programmed necrosis mechanism, is involved in the pathogenesis and outcomes of sepsis. Mixed lineage kinase domain-like protein (MLKL) is a final executor of necroptosis. However, association MLKL with severity and mortality of sepsis is not well known.Objectives: The aim of the study was to assess the association of plasma MLKL with severity and outcome of sepsis.Methods: We analyzed data of 188 prospectively-enrolled critically-ill patients admitted to the intensive care unit (ICU) of Samsung Medical Center. Plasma MLKL level was measured with the enzyme-linked immunosorbent assay.Results: Of 188 critically-ill patients, 58 (30.9%) and 84 (44.7%) patients were diagnosed with sepsis and septic shock, respectively. Plasma level of MLKL increased over the groups of control, sepsis, and septic shock (1.10 ng/mL vs. 2.03 ng/mL vs. 3.00 ng/mL, P for trend < 0.001). When 142 sepsis patients were classified into the groups of high and low plasma level of MLKL according to the best cutoff level of 3.16 ng/mL, severity of illness scores of SAPS 3 score, APCHE II score, and SOFA score and lactic acid were higher in the high MLKL group. Furthermore, septic shock and patients in need of vasopressor support were more prevalent in the high MLKL group. There was a significant difference in 7-day, 28-day, and 90-day mortalities between the groups.Conclusions: Plasma level of MLKL was associated with severity of sepsis and predictive of mortality.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3764.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -